High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring

Platelets. 2013;24(6):500-2. doi: 10.3109/09537104.2012.715218. Epub 2012 Aug 23.

Authors

Isabell Bernlochner, Katharina Mayer, Tanja Morath, Siegmund Braun, Stefanie Schulz, Albert Schömig, Werner Koch, Adnan Kastrati, Dirk Sibbing

PMID: 22916844
DOI: 10.3109/09537104.2012.715218

No abstract available

Publication types

Letter

MeSH terms

Aryl Hydrocarbon Hydroxylases / genetics*
Clopidogrel
Cytochrome P-450 CYP2C19
Drug Substitution*
Heterozygote*
Humans
Percutaneous Coronary Intervention* / adverse effects
Piperazines / administration & dosage*
Platelet Aggregation Inhibitors / administration & dosage*
Prasugrel Hydrochloride
Thiophenes / administration & dosage*
Thrombosis / genetics
Thrombosis / prevention & control
Ticlopidine / administration & dosage
Ticlopidine / analogs & derivatives*

Substances

Piperazines
Platelet Aggregation Inhibitors
Thiophenes
Clopidogrel
Aryl Hydrocarbon Hydroxylases
CYP2C19 protein, human
Cytochrome P-450 CYP2C19
Prasugrel Hydrochloride
Ticlopidine